What is driving Retinitis pigmentosa market forward?

Retinitis Pigmentosa is a heterogeneous, progressive disease, leading to worsening of the vision over time.
Treatment of Retinitis Pigmentosa is as big of a challenge as its diagnosis is.
Management, prognosis, diagnosis of the disease has always been an uphill task. Incomplete understanding, heterogeneity, complex pathophysiology and involvement of numerous genes are the major hurdles needed to be overcome in the Retinitis pigmentosa market

Several pharma and biotech companies including HORA-RPE65 ( Horama), AAV8-RPGR (NIGHTSTAR THERAPEUTICS), jCell (jCyte, Inc.), Renexus (NT-501; Neurotech Pharmaceuticals, Inc.), and hRPC (RENEURON LIMITED) are expected to enter into Retinitis pigmentosa market in the coming decade.

For more details visit: https://www.delveinsight.com/blog/retinitis-pigmentosa-market-analysis/

#Retinitis #Pigmentosa #RetinitisPigmentosa #RP #retina #vision #genetic #disorders #eyecare #eyehealth #eyedisease #visionloss